|
1
|
Tural D, Ozturk M, Selcukbiricik F, et al:
Preoperative chemoradiotherapy improves local recurrence free
survival in locally advanced rectal cancer. J BUON. 18:385–390.
2013.PubMed/NCBI
|
|
2
|
Valentini V, Coco C, Picciocchi A, et al:
Does downstaging predict improved outcome after preoperative
chemoradiation for extraperitoneal locally advanced rectal cancer?
A long-term analysis of 165 patients. Int J Radiat Oncol Biol Phys.
53:664–674. 2002. View Article : Google Scholar
|
|
3
|
Ho-Pun-Cheung A, Assenat E,
Bascoul-Mollevi C, et al: A large-scale candidate gene approach
identifies SNPs in SOD2 and IL13 as predictive markers of response
to preoperative chemoradiation in rectal cancer. Pharmacogenomics
J. 11:437–443. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wong MT, Lim JF, Ho KS, et al: Radiation
proctitis: a decade’s experience. Singapore Med J. 51:315–319.
2010.
|
|
5
|
Torres-Roca JF and Stevens CW: Predicting
response to clinical radiotherapy: past, present, and future
directions. Cancer Control. 15:151–156. 2008.PubMed/NCBI
|
|
6
|
Benn P, Cuckle H and Pergament E:
Non-invasive prenatal testing for aneuploidy: current status and
future prospects. Ultrasound Obstet Gynecol. 42:15–33. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liao GJ, Chiu RW and Lo YM: Prenatal
assessment of fetal chromosomal and genetic disorders through
maternal plasma DNA analysis. Pathology. 44:69–72. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hahn S, Rusterholz C, Hösli I and Lapaire
O: Cell-free nucleic acids as potential markers for preeclampsia.
Placenta. 32(Suppl 1): S17–S20. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
De Mattos-Arruda L, Cortes J, Santarpia L,
et al: Circulating tumour cells and cell-free DNA as tools for
managing breast cancer. Nat Rev Clin Oncol. 10:377–389.
2013.PubMed/NCBI
|
|
10
|
Ghorbian S and Ardekani AM: Non-invasive
detection of esophageal cancer using genetic changes in circulating
cell-free DNA. Avicenna J Med Biotechnol. 4:3–13. 2012.PubMed/NCBI
|
|
11
|
Kamat AA, Baldwin M, Urbauer D, et al:
Plasma cell-free DNA in ovarian cancer: an independent prognostic
biomarker. Cancer. 116:1918–1925. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ellinger J, Müller SC, Stadler TC, et al:
The role of cell-free circulating DNA in the diagnosis and
prognosis of prostate cancer. Urol Oncol. 29:124–129. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
van der Vaart M and Pretorius PJ: The
origin of circulating free DNA. Clin Chem. 53:22152007.PubMed/NCBI
|
|
14
|
Lecomte T, Berger A, Zinzindohoué F, et
al: Detection of free-circulating tumor-associated DNA in plasma of
colorectal cancer patients and its association with prognosis. Int
J Cancer. 100:542–548. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cheng C, Omura-Minamisawa M, Kang Y, et
al: Quantification of circulating cell-free DNA in the plasma of
cancer patients during radiation therapy. Cancer Sci. 100:303–309.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Agostini M, Pucciarelli S, Enzo MV, et al:
Circulating cell-free DNA: a promising marker of pathologic tumor
response in rectal cancer patients receiving preoperative
chemoradiotherapy. Ann Surg Oncol. 18:2461–2468. 2011. View Article : Google Scholar
|
|
17
|
Mulcahy HE, Lyautey J, Lederrey C, et al:
A prospective study of K-ras mutations in the plasma of pancreatic
cancer patients. Clin Cancer Res. 4:271–275. 1998.PubMed/NCBI
|
|
18
|
Koutsimpelas D, Pongsapich W, Heinrich U,
et al: Promoter methylation of MGMT, MLH1 and
RASSF1A tumor suppressor genes in head and neck squamous
cell carcinoma: Pharmacological genome demethylation reduces
proliferation of head and neck squamous carcinoma cells. Oncol Rep.
27:1135–1141. 2012.
|
|
19
|
Dworak O, Keilholz L and Hoffmann A:
Pathological features of rectal cancer after preoperative
radiochemotherapy. Int J Colorectal Dis. 12:19–23. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sameer AS: Colorectal cancer: molecular
mutations and polymorphisms. Front Oncol. 3:1142013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gagliardi G, Biricotti M, Failli A, et al:
Colorectal carcinoma and folate. Ann Ital Chir. 84:123–131.
2013.PubMed/NCBI
|
|
22
|
Wong RK, Tandan V, De Silva S and
Figueredo A: Pre-operative radiotherapy and curative surgery for
the management of localized rectal carcinoma. Cochrane Database
Syst Rev. 2:CD0021022007.PubMed/NCBI
|
|
23
|
Kilic D, Yalman D, Aksu G, et al: Impact
of adjuvant chemoradiotherapy for rectal cancer on the long-term
quality of life and late side effects: a multicentric clinical
evaluation by the Turkish Oncology Group. Asian Pac J Cancer Prev.
13:5741–5746. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
De Caluwé L, Van Nieuwenhove Y and Ceelen
WP: Preoperative chemoradiation versus radiation alone for stage II
and III resectable rectal cancer. Cochrane Database Syst Rev.
2:CD0060412013.
|
|
25
|
González-Masiá JA, García-Olmo D and
García-Olmo DC: Circulating nucleic acids in plasma and serum
(CNAPS): applications in oncology. Onco Targets Ther. 6:819–832.
2013.PubMed/NCBI
|
|
26
|
Gorges TM, Schiller J, Schmitz A, et al:
Cancer therapy monitoring in xenografts by quantitative analysis of
circulating tumor DNA. Biomarkers. 17:498–506. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mouliere F, Robert B, Arnau Peyrotte E, et
al: High fragmentation characterizes tumour-derived circulating
DNA. PLoS One. 6:e234182011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Thierry AR, Mouliere F, Gongora C, et al:
Origin and quantification of circulating DNA in mice with human
colorectal cancer xenografts. Nucleic Acids Res. 38:6159–6175.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mouliere F and Thierry AR: The importance
of examining the proportion of circulating DNA originating from
tumor, microenvironment and normal cells in colorectal cancer
patients. Expert Opin Biol Ther. 12(Suppl 1): S209–S215. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zitt M, Müller HM, Rochel M, et al:
Circulating cell-free DNA in plasma of locally advanced rectal
cancer patients undergoing preoperative chemoradiation: a potential
diagnostic tool for therapy monitoring. Dis Markers. 25:159–165.
2008. View Article : Google Scholar
|
|
31
|
Zitt M, Zitt M, Müller HM, et al:
Disseminated tumor cells in peripheral blood: a novel marker for
therapy response in locally advanced rectal cancer patients
undergoing preoperative chemoradiation. Dis Colon Rectum.
49:1484–1491. 2006. View Article : Google Scholar
|
|
32
|
Liggett TE, Melnikov AA, Marks JR and
Levenson VV: Methylation patterns in cell-free plasma DNA reflect
removal of the primary tumor and drug treatment of breast cancer
patients. Int J Cancer. 128:492–499. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jing R, Cui M, Wang H and Ju S: Cell-free
DNA: characteristics, detection and its applications in myocardial
infarction. Curr Pharm Des. 19:5135–5145. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lilleberg SL, Durocher J, Sanders C, et
al: High sensitivity scanning of colorectal tumors and matched
plasma DNA for mutations in APC, TP53, K-RAS, and BRAF genes with a
novel DHPLC fluorescence detection platform. Ann NY Acad Sci.
1022:250–256. 2004. View Article : Google Scholar
|
|
35
|
Wang JY, Hsieh JS, Chang MY, et al:
Molecular detection of APC, K-ras, and p53
mutations in the serum of colorectal cancer patients as circulating
biomarkers. World J Surg. 28:721–726. 2004.
|
|
36
|
Misale S, Yaeger R, Hobor S, et al:
Emergence of KRAS mutations and acquired resistance to
anti-EGFR therapy in colorectal cancer. Nature. 486:532–536.
2012.
|
|
37
|
Dobrzycka B, Terlikowski SJ, Mazurek A, et
al: Mutations of the KRAS oncogene in endometrial hyperplasia and
carcinoma. Folia Histochem Cytobiol. 47:65–68. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dobrzycka B, Terlikowski SJ, Mazurek A, et
al: Circulating free DNA, p53 antibody and mutations of KRAS
gene in endometrial cancer. Int J Cancer. 127:612–621. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Roberts PJ and Stinchcombe TE: KRAS
mutation: should we test for it, and does it matter? J Clin Oncol.
31:1112–1121. 2013. View Article : Google Scholar
|
|
40
|
Morgan SR, Whiteley J, Donald E, et al:
Comparison of KRAS mutation assessment in tumor DNA and
circulating free DNA in plasma and serum samples. Clin Med Insights
Pathol. 5:15–22. 2012.
|
|
41
|
Nygaard AD, Garm Spindler KL, Pallisgaard
N, et al: The prognostic value of KRAS mutated plasma DNA in
advanced non-small cell lung cancer. Lung Cancer. 79:312–317. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Spindler KL, Pallisgaard N, Vogelius I and
Jakobsen A: Quantitative cell-free DNA, KRAS, and
BRAF mutations in plasma from patients with metastatic
colorectal cancer during treatment with cetuximab and irinotecan.
Clin Cancer Res. 18:1177–1185. 2012.
|
|
43
|
Fukushima T, Takeshima H and Kataoka H:
Anti-glioma therapy with temozolomide and status of the DNA-repair
gene MGMT. Anticancer Res. 29:4845–4854. 2009.PubMed/NCBI
|
|
44
|
Psofaki V, Kalogera C, Tzambouras N, et
al: Promoter methylation status of hMLH1, MGMT, and
CDKN2A/p16 in colorectal adenomas. World J Gastroenterol.
16:3553–3560. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Rivera AL, Pelloski CE, Gilbert MR, et al:
MGMT promoter methylation is predictive of response to radiotherapy
and prognostic in the absence of adjuvant alkylating chemotherapy
for glioblastoma. Neuro Oncol. 12:116–121. 2010. View Article : Google Scholar : PubMed/NCBI
|
